Leap Chem Co., Ltd. | China | Inquire | ||
---|---|---|---|---|
![]() |
+86 (852) 3060-6658 | |||
![]() |
market19@leapchem.com | |||
![]() |
QQ chat | |||
Chemical manufacturer since 2006 | ||||
chemBlink standard supplier since 2015 | ||||
Turtle Pharma Private Limited | India | Inquire | ||
---|---|---|---|---|
![]() |
+91 9850998504 | |||
![]() |
info@turtlepharma.com | |||
Chemical manufacturer since 2015 | ||||
chemBlink standard supplier since 2024 | ||||
Classification | API >> Synthetic anti-infective drugs >> Quinolone |
---|---|
Name | Moxifloxacin hydrochloride monohydrate |
Synonyms | 7-[(4aS,7aS)-1,2,3,4,4a,5,7,7a-octahydropyrrolo[3,4-b]pyridin-6-yl]-1-cyclopropyl-6-fluoro-8-methoxy-4-oxoquinoline-3-carboxylic acid;hydrate;hydrochloride |
Molecular Structure | ![]() |
Molecular Formula | C21H24FN3O4.HCl.H2O |
Molecular Weight | 455.91 |
CAS Registry Number | 192927-63-2 |
EC Number | 833-744-7 |
SMILES | COC1=C2C(=CC(=C1N3C[C@@H]4CCCN[C@@H]4C3)F)C(=O)C(=CN2C5CC5)C(=O)O.O.Cl |
Hazard Symbols |
| ||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Hazard Statements | H341 Details | ||||||||||||
Precautionary Statements | P203-P280-P318-P405-P501 Details | ||||||||||||
Hazard Classification | |||||||||||||
| |||||||||||||
Moxifloxacin hydrochloride monohydrate is a potent antibiotic within the fluoroquinolone class, developed to treat a variety of bacterial infections. First introduced in the late 1990s, moxifloxacin represents a significant advancement in antibiotic therapy, offering a broader spectrum of activity and enhanced efficacy compared to earlier generations of fluoroquinolones. The discovery of moxifloxacin was part of an effort to address the limitations of earlier fluoroquinolones, such as ciprofloxacin and norfloxacin. Moxifloxacin is a third-generation fluoroquinolone, designed with a chemical structure that enhances its ability to target and inhibit bacterial DNA gyrase and topoisomerase IV—key enzymes required for bacterial DNA replication and repair. This mechanism effectively disrupts bacterial cell division, leading to bacterial cell death. Moxifloxacin hydrochloride monohydrate is used primarily for treating respiratory tract infections. It is effective against pathogens responsible for conditions such as community-acquired pneumonia, acute exacerbations of chronic bronchitis, and sinusitis. The drug's activity against common respiratory pathogens, including *Streptococcus pneumoniae* and *Haemophilus influenzae*, makes it a valuable option for managing these infections. In addition to respiratory infections, moxifloxacin is prescribed for skin infections like cellulitis and abscesses, as well as intra-abdominal infections. Its broad-spectrum efficacy and good tissue penetration allow it to address a wide range of bacterial infections, making it a versatile choice in antibiotic therapy. Moxifloxacin is administered both orally and intravenously. The oral form, typically available as tablets, is used for outpatient treatment, while the intravenous form is employed in hospital settings for severe infections or when oral administration is not possible. The drug is usually given for a short course, depending on the infection and its severity. One of the notable benefits of moxifloxacin is its long half-life, which supports once-daily dosing. This dosing schedule simplifies treatment regimens and improves patient adherence. Moxifloxacin also has a relatively lower risk of drug interactions compared to some other antibiotics, enhancing its clinical utility. However, moxifloxacin is not without potential side effects. Common adverse effects include gastrointestinal issues, such as nausea and diarrhea, as well as headache and dizziness. Rare but serious side effects may include tendonitis or tendon rupture, particularly in older adults or individuals with certain predisposing conditions. Overall, moxifloxacin hydrochloride monohydrate represents an important advancement in the treatment of bacterial infections. Its development has provided a powerful tool for managing infections that are resistant to older antibiotics, reflecting significant progress in fluoroquinolone therapy. References Patterson, S. and Elston, M., 2002. Moxifloxacin: A review of its use in the treatment of respiratory and skin infections. Clinical Therapeutics, 24(4), pp. 568-582. Kemp, M. and Dorr, S.H., 2004. Moxifloxacin in the treatment of bacterial infections: A review. Journal of Antimicrobial Chemotherapy, 54(1), pp. 22-30. Friedland, I.R. and Edwards, R.F., 2006. The efficacy and safety of moxifloxacin: A review. International Journal of Antimicrobial Agents, 27(4), pp. 331-340. |
Market Analysis Reports |
List of Reports Available for Moxifloxacin hydrochloride monohydrate |